User login
Evidence linking tissue and peripheral eosinophilia with ulcerative colitis (UC) activity and severity was found in a retrospective chart review of pediatric UC cases.
Further, the review found both types of eosinophilia linked with the need for step-up therapy or corticosteroid therapy in the first year following UC diagnosis.
Sara Morgenstern, MD, of Tel Aviv University, and her coauthors reviewed all pediatric UC cases diagnosed between ages 0 and 17 years at the Schneider Children’s Hospital of Israel, Petah Tikva, between 1990 and 2015. Of 96 children diagnosed with UC by colonoscopy and followed for a median of 13 years, 31 had severe eosinophilia at the time of diagnosis, compared with 40 who had mild eosinophilia, and 25 who had a normal tissue eosinophil count. After remission, 77 had a normal eosinophilia and 19 had mild eosinophilia.
“At diagnosis, at follow-up with histologic activity and at follow-up with histologic remission, peripheral eosinophilia was demonstrated in 27%, 30% and 8%, respectively,” Dr. Morgenstern and her coauthors wrote. In the control group, 5% had peripheral eosinophilia, a significant difference (Dig Liver Dis. 2017 Feb;49[2]:170-4).
Disease activity and severity, as measured using the Pediatric UC Activity Index score, correlated significantly with tissue and blood eosinophil counts at diagnosis (P = .02 and P = .01, respectively). Disease activity and severity also correlated significantly with corticosteroid therapy, immunomodulatory therapy, and biologic therapy during the first year following diagnosis (P = .018, .04, and .05 for tissue eosinophilia; P = .013, .01, and .04 for peripheral eosinophilia, respectively).
“These findings may suggest that both tissue and peripheral eosinophilia may serve as a diagnostic marker for disease activity, severity, and short-term outcomes also in the pediatric population,” they wrote.
Dr. Morgenstern and her coauthors had no relevant financial disclosures.
Evidence linking tissue and peripheral eosinophilia with ulcerative colitis (UC) activity and severity was found in a retrospective chart review of pediatric UC cases.
Further, the review found both types of eosinophilia linked with the need for step-up therapy or corticosteroid therapy in the first year following UC diagnosis.
Sara Morgenstern, MD, of Tel Aviv University, and her coauthors reviewed all pediatric UC cases diagnosed between ages 0 and 17 years at the Schneider Children’s Hospital of Israel, Petah Tikva, between 1990 and 2015. Of 96 children diagnosed with UC by colonoscopy and followed for a median of 13 years, 31 had severe eosinophilia at the time of diagnosis, compared with 40 who had mild eosinophilia, and 25 who had a normal tissue eosinophil count. After remission, 77 had a normal eosinophilia and 19 had mild eosinophilia.
“At diagnosis, at follow-up with histologic activity and at follow-up with histologic remission, peripheral eosinophilia was demonstrated in 27%, 30% and 8%, respectively,” Dr. Morgenstern and her coauthors wrote. In the control group, 5% had peripheral eosinophilia, a significant difference (Dig Liver Dis. 2017 Feb;49[2]:170-4).
Disease activity and severity, as measured using the Pediatric UC Activity Index score, correlated significantly with tissue and blood eosinophil counts at diagnosis (P = .02 and P = .01, respectively). Disease activity and severity also correlated significantly with corticosteroid therapy, immunomodulatory therapy, and biologic therapy during the first year following diagnosis (P = .018, .04, and .05 for tissue eosinophilia; P = .013, .01, and .04 for peripheral eosinophilia, respectively).
“These findings may suggest that both tissue and peripheral eosinophilia may serve as a diagnostic marker for disease activity, severity, and short-term outcomes also in the pediatric population,” they wrote.
Dr. Morgenstern and her coauthors had no relevant financial disclosures.
Evidence linking tissue and peripheral eosinophilia with ulcerative colitis (UC) activity and severity was found in a retrospective chart review of pediatric UC cases.
Further, the review found both types of eosinophilia linked with the need for step-up therapy or corticosteroid therapy in the first year following UC diagnosis.
Sara Morgenstern, MD, of Tel Aviv University, and her coauthors reviewed all pediatric UC cases diagnosed between ages 0 and 17 years at the Schneider Children’s Hospital of Israel, Petah Tikva, between 1990 and 2015. Of 96 children diagnosed with UC by colonoscopy and followed for a median of 13 years, 31 had severe eosinophilia at the time of diagnosis, compared with 40 who had mild eosinophilia, and 25 who had a normal tissue eosinophil count. After remission, 77 had a normal eosinophilia and 19 had mild eosinophilia.
“At diagnosis, at follow-up with histologic activity and at follow-up with histologic remission, peripheral eosinophilia was demonstrated in 27%, 30% and 8%, respectively,” Dr. Morgenstern and her coauthors wrote. In the control group, 5% had peripheral eosinophilia, a significant difference (Dig Liver Dis. 2017 Feb;49[2]:170-4).
Disease activity and severity, as measured using the Pediatric UC Activity Index score, correlated significantly with tissue and blood eosinophil counts at diagnosis (P = .02 and P = .01, respectively). Disease activity and severity also correlated significantly with corticosteroid therapy, immunomodulatory therapy, and biologic therapy during the first year following diagnosis (P = .018, .04, and .05 for tissue eosinophilia; P = .013, .01, and .04 for peripheral eosinophilia, respectively).
“These findings may suggest that both tissue and peripheral eosinophilia may serve as a diagnostic marker for disease activity, severity, and short-term outcomes also in the pediatric population,” they wrote.
Dr. Morgenstern and her coauthors had no relevant financial disclosures.
FROM DIGESTIVE AND LIVER DISEASE
Key clinical point:
Major finding: At diagnosis, at follow-up with histologic activity, and at follow-up with histologic remission, peripheral eosinophilia was demonstrated in 27%, 30%, and 8%, respectively.
Data source: Ninety-six children diagnosed with UC by colonoscopy.
Disclosures: Dr. Morgenstern and her coauthors had no relevant financial disclosures.